论文部分内容阅读
对３４例原发性肝癌（ＰＬＣ）患者外周血可溶性白细胞介素－２受体（ｓＩＬ－２Ｒ）、ＮＫ活性、Ｔ淋巴细胞亚群进行测定。结果：ＰＬＣ患者ｓＩＬ－２Ｒ水平明显高于健康对照组（Ｐ＜０．０１），ＮＫ活性、Ｔ淋巴细胞亚群ＣＤ３、ＣＤ４、ＣＤ４／ＣＤ比值均低于正常人（Ｐ＜０．０１），而ＣＤ８高于正常对照组（Ｐ＜０．０５）。Ⅱ、Ⅲ期ＰＬＣ患者ｓＩＬ－２Ｒ水平显著高于Ⅰ期患者（Ｐ＜０．０１）。ｓＩＬ－２Ｒ水平≥１０００ｕ／ｍｌ、５００～１０００ｕ／ｍｌ、＜５００ｕ／ｍｌ者６个月内的死亡率分别为８０．０％、２９．４％、０％。肝癌切除术后２周ｓＩＬ－２Ｒ水平较术前低（Ｐ＜０．０５），免疫治疗后４周ｓＩＬ－２Ｒ水平亦较治疗前低（Ｐ＜０．０５）。细胞免疫水平都有所改善。提示测定外周血ｓＩＬ－２Ｒ水平可作为ＰＬＣ的免疫状态、病情严重程度、疗效观察及预后估计的生物学指标。
The levels of soluble interleukin-2 receptor (sIL-2R), NK activity, and T lymphocyte subsets in peripheral blood of 34 patients with primary liver cancer (PLC) were measured. Results: The levels of sIL-2R in PLC patients were significantly higher than those in healthy controls (P<0.01), and the NK activity, T lymphocyte subsets CD3, CD4, and CD4/CD ratios were all lower than those in normal controls (P<0.01). The CD8 was higher than the normal control group (P<0.05). The level of sIL-2R was significantly higher in stage II and III PLC patients than in stage I patients (P<0.01). The mortality rate of sIL-2R ≥1000u/ml, 500～1000u/ml, and <500u/ml within 6 months was 80.0%, 29.4%, and 0%, respectively. The level of sIL-2R was lower in the 2 weeks after resection of hepatocellular carcinoma than in the preoperative (P<0.05), and the level of sIL-2R was also lower in the 4 weeks after immunotherapy than before the treatment (P<0.05). The level of cellular immunity has improved. The measurement of sIL-2R in peripheral blood can be used as a biological indicator of PLC’s immune status, severity of illness, curative effect observation, and prognosis estimation.